Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Atevirdine Mesylate. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA2A | P08913 | 1/20 | 0.59 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.59 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.59 |
| ▸ | MAOA | P21397 | 1/20 | 0.59 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.59 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.59 |
| ▸ | MDH1 | P40925 | 1/20 | 0.59 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.59 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.59 |
| ▸ | DRD2 | P14416 | 5/20 | 0.54 |
| ▸ | DRD3 | P35462 | 5/20 | 0.54 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.49 |
| ▸ | MEN1 | O00255 | 3/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.47 |
| ▸ | NPC1 | O15118 | 1/20 | 0.47 |
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
| ▸ | FPR2 | P25090 | 2/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Atevirdine Mesylate SCHEMBL29636966 | 1.00 | ADRA2A (0.59) | ADRA2AADORA3CHRM1MAOATBXA2R | |
| Atevirdine Mesylate SCHEMBL29365699 | 0.97 | HRH4 (0.57) | ADRA2AADORA3CHRM1MAOATBXA2R | |
| Atevirdine Mesylate SCHEMBL356038 | 0.97 | HRH4 (0.57) | ADRA2AADORA3CHRM1MAOATBXA2R | |
| Atevirdine Mesylate SCHEMBL29377031 | 0.97 | HRH4 (0.57) | ADRA2AADORA3CHRM1MAOATBXA2R | |
| SCHEMBL2818013 | 0.85 | ADRA2A (0.58) | ADRA2AADORA3CHRM1MAOATBXA2R | |
| SCHEMBL18329597 | 0.82 | ADRA2A (0.51) | ADRA2AADORA3CHRM1MAOATBXA2R | |
| SCHEMBL29683747 | 0.80 | ADRA2A (0.75) | ADRA2AADORA3CHRM1MAOATBXA2R | |
| SCHEMBL6362889 | 0.80 | ADRA2A (0.75) | ADRA2AADORA3CHRM1MAOATBXA2R | |
| SCHEMBL12494603 | 0.80 | ADRA2A (0.77) | ADRA2AADORA3CHRM1MAOATBXA2R | |
| SCHEMBL8985854 | 0.79 | ALDH1A1 (0.49) | DRD2DRD3KMT2AMEN1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1044 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024215771-A1 | SUBSTITUTED PHENYL ETHYNYL PYRIMIDINES AS POTENT INHIBITORS OF ALPHAVIRUSES | SOUTHERN RESEARCH INSTITUTE (US) | 2024-10-17 | — | — | WO | claimed |
| EP-4262812-A1 | 6-AZA-NUCLEOSIDE PRODRUGS AS ANTIVIRAL AGENTS FOR TREATING VIRUS INFECTIONS | Southern Research Institute (US) | 2023-10-25 | — | — | EP | claimed |
| WO-2023122212-A2 | SUBSTITUTED PHENYL ETHYNYL PYRIDINE CARBOXAMIDES AS POTENT INHIBITORS OF SARS VIRUS | SOUTHERN RESEARCH INSTITUTE (US) | 2023-06-29 | — | — | WO | claimed |
| EP-4125845-A1 | NOVEL 2-PYRIMIDONE ANALOGS AS POTENT ANTIVIRAL AGENTS AGAINST ALPHAVIRUSES | Southern Research Institute (US) | 2023-02-08 | — | — | EP | claimed |
| EP-4021413-A1 | LIPOSOMAL TROPONOID COMPOUND FORMULATIONS | United States Government as Represented by The Department of Veterans Affairs (US) | 2022-07-06 | — | — | EP | claimed |
| WO-2022133323-A1 | 6-AZA-NUCLEOSIDE PRODRUGS AS ANTIVIRAL AGENTS FOR TREATING VIRUS INFECTIONS | SOUTHERN RESEARCH INSTITUTE (US) | 2022-06-23 | — | — | WO | claimed |
| WO-2021203048-A1 | NOVEL 2-PYRIMIDONE ANALOGS AS POTENT ANTIVIRAL AGENTS AGAINST ALPHAVIRUSES | SOUTHERN RESEARCH INSTITUTE (US) | 2021-10-07 | — | — | WO | claimed |
| US-20210299143-A1 | USE OF ANTAGONISTS TO THE NUCLEAR STEROID RECEPTOR TO INHIBIT CORONAVIRUSES | Spectral Analytics, Inc. (US) | 2021-09-30 | — | — | US | claimed |
| WO-2021041776-A1 | LIPOSOMAL TROPONOID COMPOUND FORMULATIONS | UNITED STATES GOVERNMENT AS REPRESENTED BY THE DEPARTMENT OF VETERANS AFFAIRS (US) | 2021-03-04 | — | — | WO | claimed |
| US-20130252945-A1 | AMORPHOUS BIOINORGANIC IONIC LIQUID COMPOSITIONS COMPRISING PHARMACEUTICALS | LOS ALAMOS NAT SECURITY LLC (US) | 2013-09-26 | — | — | US | claimed |
| US-20040131628-A1 | Nucleic acids for the treatment of disorders associated with microorganisms | BRATZLER ROBERT L (US) | 2004-07-08 | — | — | US | claimed |
| EP-1434602-A2 | CPG FORMULATIONS AND RELATED METHODS | Merial Limited (US) | 2004-07-07 | — | — | EP | claimed |
| US-20040092583-A1 | Treatment for inhibiting neoplastic lesions | SHANAHAN-PRENDERGAST ELIZABETH (IE) | 2004-05-13 | — | — | US | claimed |
| US-20040077601-A1 | Methods and compositions relating to isoleucine boroproline compounds | POINT THERAPEUTICS, INC. | 2004-04-22 | — | — | US | claimed |
| WO-2004004658-A2 | METHODS AND COMPOSITIONS RELATING TO ISOLEUCINE BOROPROLINE COMPOUNDS | POINT THERAPEUTICS, INC. (US) | 2004-01-15 | — | — | WO | claimed |
| EP-1351678-A2 | TREATMENT FOR INHIBITING NEOPLASTIC LESIONS USING INCENSOLE AND/OR FURANOGERMACRENS | Shanahan-Prendergast, Elizabeth (IE) | 2003-10-15 | — | — | EP | claimed |
| US-6576636-B2 | Treating a noncentral nervous system by administering a covalent conjugate of a C8-26, unbranched, naturally occurring fatty acid and a drug, provided the drug is not an adenosine receptor agonist/antagonist; anticarcinogenics | PROTARGA, INC. | 2003-06-10 | — | — | US | claimed |
| WO-2003030934-A2 | CPG FORMULATIONS AND RELATED METHODS | MERIAL LIMITED (US) | 2003-04-17 | — | — | WO | claimed |
| WO-2002053138-A2 | TREATMENT FOR INHIBITING NEOPLASTIC LESIONS USING INCENSOLE AND/OR FURANOGERMACRENS | SHANAHAN-PRENDERGAST ELISABETH (IE) | 2002-07-11 | — | — | WO | claimed |
| WO-2001097749-A2 | THE USE OF SYNTHETIC, NON-HORMONAL 21-AMINOSTEROIDS AND THEREOF | KOTZE, GAVIN, SALOMON (ZA) | 2001-12-27 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210299143-A1 | USE OF ANTAGONISTS TO THE NUCLEAR STEROID RECEPTOR TO INHIBIT CORONAVIRUSES | NCOA1, NCOA2, NCOA3 | ADRA2A 791/4885ADORA3 2910/4885CHRM1 2985/4885 |
| US-20040092583-A1 | Treatment for inhibiting neoplastic lesions | VHL, IDH2, AIFM2 | ADRA2A 3753/4885ADORA3 4024/4885CHRM1 2918/4885 |
| US-20130252945-A1 | AMORPHOUS BIOINORGANIC IONIC LIQUID COMPOSITIONS COMPRISING PHARMACEUTICALS | MCOLN1, PYM1, MCOLN2 | ADRA2A 2878/4885ADORA3 2926/4885CHRM1 1277/4885 |
| US-20040077601-A1 | Methods and compositions relating to isoleucine boroproline compounds | BCAT1, BCAT2, APOB | ADRA2A 270/4885ADORA3 2733/4885CHRM1 2457/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.